Printer Friendly

RHEUMATOID ARTHRITIS RESULTS FROM INDEPENDENT CLINICAL TRIAL OF PROSORBA COLUMN REPORTED BY IMRE CORPORATION

RHEUMATOID ARTHRITIS RESULTS FROM INDEPENDENT CLINICAL TRIAL OF PROSORBA
 COLUMN REPORTED BY IMRE CORPORATION
 SEATTLE, Oct. 8 /PRNewswire/ -- IMRE Corporation (NASDAQ: IMRE), the leader in the field of immunoadsorption, announced today positive results from the treatment of 11 refractory rheumatoid arthritis with the company's PROSORBA (R) column. Ten out of 11 patients showed improvement with two completely remitting. Rheumatoid arthritis affects approximately 2.5 million patients in the United States.
 Drs. Craig Wiesenhutter and Juergen Bertram, who supervised the independent trial at the Coeur d'Alene Arthritis Clinic and North Idaho Cancer Center in Coeur d'Alene, Idaho, will present these findings at the 1992 annual meeting of the American College of Rheumatology in Atlanta on Oct. 12, 1992. An abstract describing this study was released by the American College of Rheumatology to all of its members this week. Additional trials are now underway which will include 14 patients at three different medical institutions.
 The 11 patients participating in the test had been treated with non- steroidal anti-inflammatory drugs without success for an average period of 12.4 years. Patients were treated with the PROSORBA column twice a week for three weeks and then once a week for an additional nine weeks for a total of 15 treatments. Of the 11 patients, two had complete remission of their disease, eight had significant reduction in their pain index, number of painful joints, swelling index and the number of swollen joints. Patients were all evaluated by the "Criteria for Clinical Remission in Rheumatoid Arthritis" used by the American Rheumatism Association (ARA). All patients experienced flu-like symptoms following the treatment which lasted for 1 to 24 hours.
 Dr. Frank Jones, chairman and chief executive officer of IMRE, said, "These encouraging improvements due to PROSORBA column treatments in this small group of patients indicates its potential application to rheumatoid arthritis, the largest patient population for which this treatment has been tested."
 The PROSORBA column was developed and patented by IMRE scientists and has been marketing approved by the U.S. Food and Drug Administration (FDA) for the treatment of immune thrombocytopenic purpura (ITP), a bleeding disorder. The FDA has also granted Expedited Review status for IMRE's Premarket Approval Application (PMA) for use of the column for treatment of chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (C-TTP/HUS), a life-threatening disease for which there is no satisfactory alternative therapy.
 The PROSORBA column is a disposable one-time use cylindrical canister about three inches in diameter and three inches in height. It contains solid granules of silica which have a molecule bound to them which can remove immune suppressor molecules from a patient's blood plasma. Following removal of this immune suppressor, the body's immune system acts more normally and can combat the disease. In the two-hour procedure, a patient's plasma is separated from the blood cells, passed through the column, remixed with the cells and re-infused into the same patient.
 -0- 10/8/92
 /CONTACT: Lois Yoshida of IMRE Corporation, 206-298-9400, or Ron Stabiner of The Wall Street Group, 212-888-4848, for IMRE Corporation/
 (IMRE) CO: IMRE Corporation ST: Washington IN: MTC SU:


AH-SH -- NY070 -- 7951 10/08/92 14:29 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 8, 1992
Words:522
Previous Article:DELMARVA POWER ANNOUNCES SOLAR ELECTRICITY PROJECT
Next Article:AIRLINES EXPRESS SHOCK AT BRITISH ATTITUDE DURING U.S.-U.K. AVIATION TALKS
Topics:


Related Articles
RHEUMATOID ARTHRITIS CLINICAL TRIAL APPROVED BY FDA
IMRE ANNOUNCES PUBLICATION IN NEW ENGLAND JOURNAL OF MEDICINE
IMRE: MORE TTP/HUS DATA TO BE REQUIRED
IMRE CORP. ANNOUNCES THIRD QUARTER RESULTS; QUARTERLY SALES OF PROSORBA COLUMN REACH $2,000,000 FOR THE FIRST TIME
RHEUMATOID ARTHRITIS RESULTS FROM INDEPENDENT CLINICAL TRIAL OF PROSORBA COLUMN SHOW LONG-TERM EFFECTS
JOURNAL OF RHEUMATOLOGY PUBLISHES RESULTS OF TREATMENT OF RHEUMATOID ARTHRITIS WITH IMRE CORPORATION'S PROSORBA COLUMN
IMRE CORPORATION BEGINS KIDNEY TRANSPLANTATION CLINICAL TRIAL
IMRE CORPORATION PRESENTS A METHOD TO TREAT BLEEDING DISORDERS
IMRE CORPORATION ANNOUNCES POSITIVE RHEUMATOID ARTHRITIS CLINICAL TRIAL RESULTS
IMRE CORPORATION RECEIVES CONDITIONAL APPROVAL TO BEGIN PIVOTAL RHEUMATOID ARTHRITIS CLINICAL TRIAL

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters